Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SITC 2022 and Sitc 2022 View overview page

1:21
Ultra-pH sensitive nanoparticles increasing therapeutic index of IL-2-Fc
Jinming Gao • 1 Nov 2022
0:45
ONM-405: pH activated nanoparticle for activating NK- and T-cells in solid tumors
Jinming Gao • 1 Nov 2022
4:37
Treating PD-L1-positive NSCLC with immunotherapy alone vs chemoimmunotherapy
Biagio Ricciuti • 17 Nov 2022
6:26
Acquired mechanisms of resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti • 17 Nov 2022
1:41
Evaluation of nanoparticle encapsulation technology for clinical use
Jinming Gao • 1 Nov 2022
1:07
Anti-tumor efficacy of OMN-405 confirmed in CRC and melanoma tumor models
Jinming Gao • 1 Nov 2022
0:21
Identifying and managing patients who develop ICI-associated acute kidney injury
Shruti Gupta • 16 Nov 2022
0:59
Remaining challenges in the field of onco-nephrology
Shruti Gupta • 16 Nov 2022
0:59
Decreasing the risk of immunotherapy-related kidney damage
Shruti Gupta
1:05
Improving outcomes in ICI-associated acute kidney injury
Shruti Gupta • 16 Nov 2022
2:11
Acute kidney injury in patients receiving immune checkpoint inhibitors
Shruti Gupta • 16 Nov 2022
2:28
Targeting cold tumors with anti-PVRIG immunotherapy
Eran Ophir • 26 Oct 2022
1:29
COM701 & nivolumab in patients with metastatic MSS-CRC & liver metastases
Michael Overman • 9 Nov 2022
0:46
Key limitations of current treatment options for patients with MSS-CRC
Michael Overman • 9 Nov 2022
1:58
MEK inhib to combat antigen escape in treating poorly differentiated thyroid cancers with TSHR-CART
Claudia Manriquez Roman • 4 Nov 2022
2:06
Highlights in GI cancers from SITC 2022
J. Randolph Hecht • 15 Nov 2022
The content of VJOncology is intended for healthcare professionals